Leading science and technology company Merck Group foresees ‘sustainable growth’ across its life science, healthcare and electronics businesses after recording group net sales of €5.3bn in Q1 2025.
The positive outlook coincided with modified full-year guidance with group full-year net sales expected between €20.9-22.4bn and EBITDA pre-tax sales of €5.8-6.4bn.
The slight adjustment to the guidance in life science, Merck’s biggest business sector, relates to current uncertainties around tariffs, according to a statement.
Process solutions – the division marketing across the pharmaceutical production value chain – reclaimed its position as the main growth driver amid noticeably recovering demand while the healthcare sector saw strong sales in the cardiovascular, metabolism, and endocrinology franchise, and electronics continued to benefit from steady and strong demand for semiconductor materials.
… to continue reading this article and more, please login, register for free, or consider subscribing to gasworld
You’ve reached your weekly limit to access free articles!
Want to keep reading?
Please register for free and create a profile to gain access to this full article and gasworld’s daily news.
For access to more content including our monthly digital magazines, subscriber-only features or columns and all our other gasworld archives, please consider subscribing.
Alternatively, you can continue reading more articles as a guest on Tuesday, 10th June at 9:27AM
